Story perspectives

Nebius Stock Soars After $17.4B AI Deal with Microsoft

10/3/2025

Summary

Nebius Soars Post-Deal

Nebius Group's stock rose to about $110 after a $17.4 billion AI deal with Microsoft.
Analysts expect 231% revenue growth to $4.25 billion by 2027, with EBITDA positive in 2026.
Nebius announced a $3 billion capital raise for expansion, including data centers and GPU purchases, risking dilution.
Analysts set targets at $75–$130 amid optimism and contract risk.

Summary

Nebius Boosts Biotech

Nasdaq Biotechnology Index (NBIS) rose to about 5,007.41 on Oct 2, 2025, up 2.61% to a 1-year high, driven by AI-enabled drug discovery optimism.
Analysts say Nebius's partnership with Microsoft could boost AI compute capacity, helping biotech firms and potentially speed drug discovery.
Regulators' uncertainty persists, notably around the U.S. Inflation Reduction Act and potential drug-pricing reforms, warranting caution.

History

Historical Context

The 21st Century Cures Act, enacted in 2015, allocated $6.3 billion to accelerate medical product development and streamline drug approvals in the U.S. This legislative push reflects a broader trend towards innovation in healthcare. Nebius Group's partnership with Microsoft aims to leverage AI for drug discovery, potentially reshaping the pharmaceutical landscape while addressing regulatory challenges posed by laws like the Inflation Reduction Act.

1 of 3

Nebius Soars Post-Deal

Nebius Group's stock rose to about $110 after a $17.4 billion AI deal with Microsoft.
Analysts expect 231% revenue growth to $4.25 billion by 2027, with EBITDA positive in 2026.
Nebius announced a $3 billion capital raise for expansion, including data centers and GPU purchases, risking dilution.
Analysts set targets at $75–$130 amid optimism and contract risk.

1 / 3